Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Study Shows 19% of Breast Cancer Patients Don’t Receive Recommended Radiation After Mastectomy

February 19, 2009
Publication
Article
OncologyONCOLOGY Vol 23 No 2
Volume 23
Issue 2

One-fifth of women who should receive radiation after a mastectomy are not getting this potentially lifesaving treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

One-fifth of women who should receive radiation after a mastectomy are not getting this potentially lifesaving treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

The study looked at 396 women who were treated with a mastectomy for breast cancer. The researchers found that 19% of women who fell clearly within guidelines recommending radiation after the mastectomy did not receive that treatment. Results of the study appear online in the journal Cancer and will be published in the March 15 issue.

Postmastectomy radiation is known to decrease the risk of cancer returning in the chest wall and has been shown to reduce mortality in high-risk patients, but there has been some debate within the cancer community about who is likely to benefit most. Current guidelines recommend radiation after mastectomy for women who had particularly large tumors or cancer in four or more of their nearby lymph nodes. Even women with fewer positive lymph nodes should strongly consider radiation treatment.

Potentially Lifesaving Treatment
“There’s an identifiable high-risk group for whom there’s absolutely no debate-they need radiation after their mastectomy. Even in this group for whom it’s crystal clear, we found that only four-fifths were treated. That’s not good enough. This is a potentially lifesaving treatment,” says lead study author Reshma Jagsi, MD, DPhil, assistant professor of radiation oncology at the U-M Medical School.

The most common reason women cited for not considering radiation therapy was that their doctors did not recommend it. “Much attention has been focused on educating people that they need radiation after lumpectomy. But many women assume having a mastectomy means radiation won’t be needed. That’s not always the case, and patients choosing one surgery over another hoping to avoid radiation need to be aware of this,” Jagsi says.

Articles in this issue

Adjuvant Therapy for Colorectal Cancer: Increasingly Complex as Patients Age
A Man With Changes in the Urinary Bladder: Benign Metaplasia or Adenocarcinoma?
A Man With Changes in the Urinary Bladder: Benign Metaplasia or Adenocarcinoma?
First-Line Maintenance With Erlotinib/Bevacizumab Improves Progression-Free Survival in Advanced Lung Cancer
Study Shows 19% of Breast Cancer Patients Don’t Receive Recommended Radiation After Mastectomy
Toward Evidence-Based Management of the Dermatologic Effects of EGFR Inhibitors
Toward Evidence-Based Management of the Dermatologic Effects of EGFR Inhibitors
The Growing Importance of Skin Toxicity in EGFR Inhibitor Therapy
In Search of Rigorous Data on How to Palliate the EGFR Inhibitor–Induced Rash
Endocrine Therapy in 2009: Consideration of the Tumor and the Host
Predicting Endocrine Responsiveness: Novel Biomarkers on the Horizon
Adjuvant Chemotherapy for Colon Cancer in the Elderly: Moving From Evidence to Practice
How Should We Care for Elderly Cancer Patients?
Acai Berry
Acai Berry
Predicting Endocrine Therapy Responsiveness in Breast Cancer
Recent Videos
Patients with node-negative disease who are older and have comorbidities may not be suitable to receive CDK4/6 inhibitors.
An observed carryover effect with CDK4/6 inhibitors may reduce the risk of recurrence years after a patient stops treatment.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Related Content
Advertisement

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

Caroline Oska;Eleni Kohilakis;Jana Fox
July 15th 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats

4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats

Tarbia Hamid;Laura Manfroi;Hiral Thakkar;Samir Mitri
July 14th 2025
Article

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD, PhD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life

6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life

Muriel Statman;Marcelo Sleiman Jr;Duye Liu;Anthony Zisa;Adina Fleischmann;Kenneth Tercyak
July 12th 2025
Article

Use of TumorSight Viz may support improved consistency, precision, and efficiency in breast cancer surgery.

FDA Clears AI-Based Visualization Software for Surgical Breast Cancer Care

Russ Conroy
July 12th 2025
Article

Use of TumorSight Viz may support improved consistency, precision, and efficiency in breast cancer surgery.

Related Content
Advertisement

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

3 Intraoperative Radiotherapy: Alive and Well in the Bronx

Caroline Oska;Eleni Kohilakis;Jana Fox
July 15th 2025
Article

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats

4 Evaluating AI-Driven Responses in Breast Reconstruction: A Comparative Study of Response Formats

Tarbia Hamid;Laura Manfroi;Hiral Thakkar;Samir Mitri
July 14th 2025
Article

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.

SABCS 2024 Data Show ‘Great Steps Forward’ in Breast Cancer Care

Paolo Tarantino, MD, PhD;Matteo Lambertini, MD
January 13th 2025
Podcast

Paolo Tarantino, MD, and Matteo Lambertini, MD, PhD discuss findings related to CDK4/6 inhibitors and antibody drug conjugates presented at SABCS 2024.


6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life

6 Peer Support Programming Among Women At-Risk for Surviving Breast Cancer: Facilitators and Barriers to Community-Based Patient Navigation and the Role of Quality of Life

Muriel Statman;Marcelo Sleiman Jr;Duye Liu;Anthony Zisa;Adina Fleischmann;Kenneth Tercyak
July 12th 2025
Article

Use of TumorSight Viz may support improved consistency, precision, and efficiency in breast cancer surgery.

FDA Clears AI-Based Visualization Software for Surgical Breast Cancer Care

Russ Conroy
July 12th 2025
Article

Use of TumorSight Viz may support improved consistency, precision, and efficiency in breast cancer surgery.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.